Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
Aligos Therapeutics (Nasdaq: ALGS) will release its second quarter 2021 financial results on August 5, 2021, after U.S. market close. The company, established in 2018, focuses on developing innovative therapies for viral infections and liver diseases. Its strategy leverages extensive expertise in drug development, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Aligos aims to advance potentially best-in-class molecules in its pipeline to meet significant unmet medical needs.
- Company is focusing on developing novel therapeutics for viral infections and liver diseases.
- Established in 2018, indicating a relatively new and innovative approach in the industry.
- No specific financial results or metrics available to gauge current performance or market impact.
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Such forward-looking statements are subject to substantial risks and uncertainties, many of which may be beyond Aligos’ control and could cause Aligos’ development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, the Registration Statement on Form S-1 filed with the SEC on June 28, 2021, and its future periodic reports to be filed with the SEC. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
FAQ
When will Aligos Therapeutics report its second quarter 2021 financial results?
What is the focus of Aligos Therapeutics?
What diseases is Aligos targeting with its therapies?
What is the significance of Aligos' establishment in 2018?
